EuroBiotech—More Articles of Note | FierceBiotech


> GlaxoSmithKline offloaded its gene therapy portfolio to Orchard Therapeutics. The deal sees GSK gain a 20% stake in the gene therapy specialist and secure a stream of milestones and royalties in return for its approved portfolio and investigational pipeline. Statement

> Kenneth Newman, M.D., has resigned as Verona Pharma CMO. Release

> Genfit’s phase 3 NASH trial hit an enrollment milestone. Statement

Free Daily Newsletter

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Nanobiotix signed up to work with MD Anderson Cancer Center on its oncology drug NBTXR3. Release 

> Pharnext raised €16 million ($20 million) in a private placement. Statement

> Argenx cleared the third preclinical milestone in its ARGX-112 collaboration with LEO Pharma. Release

Source link


Please enter your comment!
Please enter your name here